Study | Overall survival (95% CI), point estimates | Statistics | ||
---|---|---|---|---|
HSCT at 2 years | HSCT at 3 years | SDCT at 3 years | ||
Aggregate comparative data | ||||
Bui-Nguyen et al21 | 32.7% | 49.4% | HR 1.26 (0.70 to 2.29), p=0.44 | |
Aggregate case series data | ||||
Bertuzzi et al22 | 20% | NR | NA | |
Bisogno et al23 | 48% | 38.9% | NA | |
Blay et al24 | NR | NR | NÁ | |
Bokemeyer et al25 | Median 13 months, range 3–19 | NA | ||
Cook et al26 | NR | 40% (24% to 58%) | NA | |
Philippe-Chomette et al27 | 51.4% (23.2% to 79.6%) | NR | NA |
Some estimates were deduced from Kaplan-Meier plots.
HSCT, autologous haematopoietic stem cell transplantation following high-dose chemotherapy; NA, not applicable; NR, not reported, SDCT, standard-dose chemotherapy.